Trials / Completed
CompletedNCT00983957
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
The Effect of the Co-administration of BMS-790052 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri-Cyclen®) in Healthy Female Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the effect of BMS-790052 on the pharmacokinetics of Ortho Tri-Cyclen® in healthy female subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-790052 | Tablets, Oral, 60 mg, once daily, 10 days |
| DRUG | Ortho Tri-Cyclen® | Tablets, Oral, once daily, 78 days |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2009-09-24
- Last updated
- 2015-10-16
- Results posted
- 2015-09-16
Locations
3 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00983957. Inclusion in this directory is not an endorsement.